Coin flip: Top analyst gives Amylyx ALS drug a 50% chance at approval as rare second adcomm approaches

Max Gelman

Senior Editor

It’s late August. We’re in the dog days of summer. Seemingly everyone in biopharma has reported their first-half earnings and taken vacation, getting some R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Coin flip: Top analyst gives Amylyx ALS drug a 50% chance at approval as rare second adcomm approaches

Max Gelman

Senior Editor

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Coin flip: Top an­a­lyst gives Amy­lyx ALS drug a 50% chance at ap­proval as rare sec­ond ad­comm ap­proach­es

Max Gelman

Senior Editor

Sign up to read this article for free.

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Coin flip: Top analyst gives Amylyx ALS drug a 50% chance at approval as rare second adcomm approaches

Pfizer looking to sell hospital drugs unit — reports

'Expertise is a real thing': FDA commissioner warns of political risk to agency

AstraZeneca CEO reaffirms commitment to China following executive's detention

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Sanofi, OpenAI, Formation Bio debut patient recruiting tool, will use in Phase 3 multiple sclerosis studies

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?